Absci

Unlocking differentiated biology with generative AI

Founded 2011

Vancouver, United States 159 employees IPO Total: $687.10M AI, Biopharma +2

General Information

Company Name Absci

Founded Year 2011

Location

Vancouver, United States

Employees 159

Industries AI, Biopharma, Biotechnology +1

Funding Stage IPO

Business Model B2B, Platform, API

Revenue Model Licensing, Performance Based, Project Based

Offices as of Oct 2026

Vancouver, United States

Social

BounceWatch is an independent company data service, not affiliated with Absci. To contact Absci, visit absci.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Absci compare?

A PDF of Absci and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Absci soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Regulatory Approval Oct 02, 2026

Absci announced key design details for their planned Phase 2 STORYLINE™ clinical trial evaluating ABS-201.

Event Participation Sep 30, 2026

Absci will be participating in the 35th European Academy of Dermatology and Venereology Congress in Vienna, presenting a poster on their ABS-201 program.

Actively Hiring Sep 29, 2026

Hiring for 4 positions in the last 30 days.

Key Role Hiring Sep 29, 2026

Hiring for key role: VP.

Tech Stack Change Sep 21, 2026

Added Hotjar to their site.

New Partnership Sep 10, 2026

Absci announced a $40 million strategic investment from Eli Lilly and Company, highlighting their commitment to women's health.

Get alerts when Absci shows new signals

About Absci

Absci is a forward-thinking company blending AI innovation with biopharmaceutical advancements. Founded in 2011 and headquartered in the United States, the company targets the intersection of AI and biopharma.

With the slogan “Unlocking differentiated biology with generative AI,” Absci emphasizes its unique approach to drug discovery. It employs a data-first AI strategy through its Integrated Drug Creation platform, crafted to design therapeutics and optimize drug leads for challenging biological targets.

Recently, the company secured a $64.00M post-IPO equity investment on 01 September 2025, underscoring investor confidence in its cutting-edge combination of biotechnology and artificial intelligence. This funding positions Absci to further enhance its pioneering drug creation technologies.

For investors, Absci represents a robust opportunity in the rapidly evolving fields of AI and biotechnology, focusing on creating differentiated therapeutics with high market potential.

Business keywords: AI Drug Creation, Generative AI, Biologics Design, De Novo AI Models, AI Lead Optimization, Synthetic Biology, Protein-Based Drugs, Bionic Proteins, Novel Drug Targets, Biotherapeutic Candidates, Integrated Drug Creation Platform, Antibody Development, Deep Learning AI, Pharmaceutical Partnerships, Cell Line Generation

Services & Products

AI Model Development

Biologics Drug Design

Partnered Program Development

Wet Lab Research

Target Customers

Pharmaceutical Companies Biotech Researchers Academic Institutions

Funding Rounds & Investors (13)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$100.00M	6	Invus, Redmile Group +4	01 Jun 2026
Post-IPO Equity	$64.00M	-		01 Sep 2025
Post-IPO Equity	$20.00M	1	AMD	01 Jan 2025
Post-IPO Equity	$75.20M	-		01 Feb 2024
IPO	$200.00M	-		01 Jul 2021
Late VC	$125.00M	7	Casdin Capital, D1 Capital Partners +5	01 Mar 2021
Series E	$65.00M	4	Casdin Capital, Redmile Group +2	01 Oct 2020
Debt Financing	$10.40M	5	Columbia Ventures, JSR Life Sciences +3	01 Jan 2020
Series D	$10.40M	2	KBI Biopharma, JSR Corporation	01 Jan 2019
Series C	$12.00M	3	Oregon Entrepreneurship Network, Greenbridge Partners +1	01 May 2018

View All 13 Funding Rounds

Latest News

View All

Revolutionizing Antibody Design with AI: Why We’re Backing Chai Discovery

Menlovc.com Aug 06, 2025

Chai Discovery Announces $70 million Series A To Transform Molecular Design

Finance.yahoo.com Aug 06, 2025

Yapay zeka odaklı sağlık girişimi Absci, 20 milyon dolar yatırım aldı

Webrazzi Jan 09, 2025

Absci Alternatives & Competitors

View All Alternatives

Absci vs

Atomwise United States

Better Medicines Faster

Grant

13 employees

AI, Biotechnology

Absci vs

AI Proteins United States

The perfect medicine is not found

Series A

39 employees

AI, Biotechnology

Absci vs

BioMap United States

Decoding life with AI Foundation Models

88 employees

AI, Life Sciences

View all alternatives

FAQ About Absci

Unlocking differentiated biology with generative AI

Absci was founded in 2011.

Absci is headquartered in Vancouver, United States.

Absci operates in AI, Biopharma, Biotechnology and Life Sciences. Its work centres on AI Drug Creation, Generative AI, Biologics Design and De Novo AI Models. Its customers include Pharmaceutical Companies, Biotech Researchers and Academic Institutions.

Absci has a B2B, Platform and API business model. Its revenue comes from Licensing, Performance Based and Project Based.

Absci has approximately 159 employees.

Absci has completed 13 funding rounds, raising a total of $687.10M. The latest funding stage is IPO.

Absci offers: AI Model Development, Biologics Drug Design, Partnered Program Development, Wet Lab Research.

Top alternatives and competitors to Absci include Atomwise, AI Proteins, BioMap, Profluent, Genesis Molecular AI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Absci and Atomwise are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Absci, https://bouncewatch.com/company/absci, updated 21 September 2026. When citing, please name BounceWatch and link this page.

Absci

General Information

Discover More

What changed at Absci recently?

About Absci

Services & Products

Target Customers

Funding Rounds & Investors (13)

Latest News

Absci Alternatives & Competitors

FAQ About Absci